CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (USD $) In Millions	Total		Common Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive (loss) Income	Treasury Stock, at Cost	Non-controlling Interests
Balance, value at Dec. 31, 2011	$ 3,715		$ 2	$ 2,347	$ 4,264	$ (8)	$ (2,912)	$ 22
Balance, shares at Dec. 31, 2011			157
Net income	592				556			36
Other comprehensive (loss) income, net of tax	22					22
Dividends declared	(130)				(130)
Distributions to noncontrolling interests	(38)							(38)
Issuance of common stock under benefit plans, value	21			4			17
Issuance of common stock under benefit plans, shares			1
Stock-based compensation expense	50			46			4
Exercise of stock options, value	162			(15)			177
Exercise of stock options, shares			3.0
Shares to cover employee payroll tax withholdings on stock issued under benefit plans, value	(20)			(20)
Tax benefits associated with stock-based compensation plans	9			9
Purchases of treasury stock, value	(200)						(200)
Purchases of treasury stock, shares			(3.0)
Other	3							3
Balance, value at Dec. 31, 2012	4,186		2	2,371	4,690	14	(2,914)	23
Balance, shares at Dec. 31, 2012			158
Net income	883	[1]			849			34
Other comprehensive (loss) income, net of tax	(22)					(22)
Dividends declared	(181)				(181)
Distributions to noncontrolling interests	(32)							(32)
Issuance of common stock under benefit plans, value	20			3			17
Issuance of common stock under benefit plans, shares			1
Stock-based compensation expense	28			24			4
Exercise of stock options, value	138			(9)			147
Exercise of stock options, shares			3.0
Shares to cover employee payroll tax withholdings on stock issued under benefit plans, value	(11)			(11)
Shares to cover employee payroll tax withholdings on stock issued under benefit plans, shares			1
Tax benefits associated with stock-based compensation plans	1			1
Purchases of treasury stock, value	(1,037)						(1,037)
Purchases of treasury stock, shares			(17.0)
Balance, value at Dec. 31, 2013	3,973		2	2,379	5,358	(8)	(3,783)	25
Balance, shares at Dec. 31, 2013			144
Net income	592	[1]			556			36
Other comprehensive (loss) income, net of tax	(19)					(19)
Dividends declared	(191)				(191)
Distributions to noncontrolling interests	(31)							(31)
Issuance of common stock under benefit plans, value	19			2			17
Issuance of common stock under benefit plans, shares			1
Stock-based compensation expense	51			48			3
Exercise of stock options, value	78			(2)			80
Exercise of stock options, shares	1.5		1.0
Shares to cover employee payroll tax withholdings on stock issued under benefit plans, value	(6)			(6)
Tax benefits associated with stock-based compensation plans	(3)			(3)
Purchases of treasury stock, value	(132)						(132)
Purchases of treasury stock, shares			(2.0)
Other	(1)							(1)
Balance, value at Dec. 31, 2014	$ 4,330		$ 2	$ 2,418	$ 5,723	$ (27)	$ (3,815)	$ 29
Balance, shares at Dec. 31, 2014			144

[1] In December 2012, the Company committed to a plan to sell HemoCue and completed the sale of OralDNA. During the third quarter of 2006, the Company completed its wind down of NID and classified the operations of NID as discontinued operations. Results of operations have been prepared to report the results of HemoCue, OralDNA and NID as discontinued operations for all periods presented (see Note 18).